data
limit
regard
new
human
polyomavirus
ki
polyomaviru
kipyv
wu
polyomaviru
wupyv
immunocompromis
patient
use
realtim
pcr
test
respiratori
virus
nasal
wash
sampl
collect
fi
rst
year
allogen
hematopoiet
cell
transplant
patient
specimen
collect
weekli
day
least
everi
month
one
year
hematopoiet
cell
transplant
cumul
incid
estim
kipyv
wupyv
age
year
predict
detect
kipyv
hazard
ratio
hr
wupyv
hr
detect
respiratori
viru
previou
week
predict
kipyv
detect
hr
sputum
product
wheez
associ
detect
kipyv
past
week
wupyv
past
month
associ
polyomaviru
detect
acut
graft
versu
host
diseas
cytomegaloviru
reactiv
neutropenia
lymphopenia
hospit
death
n
two
new
human
polyomavirus
ki
polyomaviru
kipyv
wu
polyomaviru
wupyv
identifi
ed
respiratori
specimen
patient
respiratori
ill
sinc
kipyv
wupyv
frequent
detect
respiratori
specimen
especi
children
respiratori
symptom
patient
coinfect
respiratori
viru
howev
kipyv
wupyv
detect
similar
rate
specimen
symptomat
patient
person
without
respiratori
symptom
suggest
virus
might
caus
respiratori
ill
immunocompet
children
two
human
polyomavirus
bk
jc
caus
mild
asymptomat
primari
infect
earli
life
follow
persist
subclin
infect
healthi
person
howev
virus
reactiv
primarili
kidney
bone
marrow
lymphoid
tissu
caus
seriou
diseas
immunocompromis
patient
similarli
reactiv
kipyv
wupyv
lymphoid
tissu
describ
among
immunosuppress
person
aid
although
clinic
consequ
reactiv
examin
kipyv
wupyv
frequent
detect
associ
respiratori
symptom
inhal
suspect
potenti
rout
transmiss
kipyv
wupyv
respiratori
pathogen
may
like
caus
respiratori
ill
immunocompromis
person
either
primari
infect
reactiv
mostli
retrospect
studi
preval
kipyv
wupyv
respiratori
specimen
includ
larg
number
immunocompromis
patient
prospect
data
avail
comprehens
describ
incid
symptom
risk
factor
outcom
associ
detect
kipyv
wupyv
respiratori
specimen
hematopoiet
cell
transplant
hct
recipi
question
particularli
relev
increas
use
multiplex
pcr
panel
detect
respiratori
virus
especi
sampl
immunocompromis
patient
investig
whether
respiratori
detect
new
polyomavirus
associ
specifi
c
outcom
patient
hct
realtim
pcr
specifi
c
kipyv
wupyv
dna
develop
use
examin
nasal
wash
specimen
collect
prospect
hct
recipi
without
respiratori
symptom
year
transplant
clinic
data
standard
symptom
survey
obtain
specimen
collect
analyz
determin
associ
respiratori
kipyv
wupyv
detect
ill
combin
nasopharyng
wash
swab
oropharyng
swab
sampl
collect
weekli
begin
week
transplant
day
everi
month
transplant
allogen
hct
recipi
enrol
prospect
surveil
studi
approv
institut
review
board
fred
hutchinson
cancer
research
center
seattl
wa
usa
particip
provid
written
inform
consent
addit
specimen
collect
respiratori
symptom
report
patient
specimen
collect
januari
particip
complet
survey
weekli
year
report
respiratori
system
symptom
clinic
laboratori
data
obtain
medic
record
inhous
duplex
realtim
taqman
pcr
develop
specifi
c
viral
protein
viral
protein
gene
kipyv
wupyv
respect
ten
microlit
extract
sampl
ad
pcr
master
mixtur
contain
kipyv
wupyv
primer
probe
tabl
sampl
pcr
cycl
threshold
valu
consid
neg
viral
copi
per
millilit
determin
use
standard
curv
gener
pcr
amplifi
cation
dilut
plasmid
contain
amplicon
sequenc
rang
concentr
copiesreact
valid
pcr
subset
kipyvposit
wupyvposit
kipyvneg
wupyvneg
sampl
blindli
retest
use
publish
assay
detect
kipyv
wupyv
inhous
pcr
sensit
dna
copiespcr
provid
sensit
copiesml
pcr
detect
jc
bk
viru
dna
subset
sampl
includ
posit
kipyv
posit
wupyv
pcr
retest
use
publish
realtim
pcr
sampl
discord
kipyv
result
includ
posit
inhous
pcr
neg
altern
pcr
neg
inhous
pcr
posit
altern
pcr
sampl
discord
wupyv
result
includ
posit
inhous
pcr
neg
altern
pcr
neg
inhous
pcr
posit
altern
pcr
sampl
discord
result
copi
ml
indic
low
level
dna
near
assay
limit
detect
sampl
test
respiratori
virus
use
multiplex
panel
realtim
taqman
revers
transcript
pcr
assay
detect
respiratori
syncyti
viru
human
metapneumoviru
infl
uenza
viru
parainfl
uenza
virus
adenovirus
coronavirus
rhinovirus
bocaviru
perform
describ
assay
detect
infl
uenza
viru
b
parainfl
uenza
viru
perform
use
reagent
thermocycl
condit
respiratori
viru
assay
substitut
specifi
c
primer
probe
set
tabl
sensit
assay
viral
copiesml
throughout
report
respiratori
viru
refer
virus
probabl
detect
kipyv
wupyv
dna
nasal
wash
sampl
transplant
transplant
estim
use
cumul
incid
curv
patient
record
censor
day
past
time
last
elig
respiratori
sampl
death
year
transplant
whichev
occur
fi
rst
death
year
within
day
last
sampl
patient
treat
compet
risk
detect
associ
kipyv
wupyv
detect
respiratori
viru
posit
estim
use
logist
regress
model
differ
kipyv
wupyv
copiesml
accord
patient
age
transplant
cooccurr
respiratori
viru
assess
use
linear
regress
model
type
robust
standard
error
calcul
account
correl
within
repeat
measur
person
cox
regress
model
fi
evalu
potenti
risk
factor
detect
kipyv
wupyv
fi
rst
year
transplant
includ
age
sex
diseas
risk
standard
high
stem
cell
sourc
donor
type
condit
regimen
myeloabl
versu
nonmyeloabl
donor
recipi
cytomegaloviru
cmv
serostatu
grade
graft
versu
host
diseas
gvhd
respiratori
viru
detect
donor
cmv
serostatu
defi
ned
neg
cord
blood
recipi
acut
gvhd
respiratori
viru
detect
treat
timedepend
covari
respiratori
viru
detect
set
respiratori
viru
detect
previou
week
otherwis
cox
regress
model
fi
evalu
risk
factor
kipyv
wupyv
detect
fi
rst
day
transplant
cmv
reactiv
model
timedepend
indic
defi
ned
antigenemia
posit
pcr
valu
antigenemia
cell
per
slide
copiesml
pcr
neutropenia
model
timedepend
covari
set
absolut
neutrophil
count
cellsmm
valu
miss
indic
previou
day
carri
forward
lymphopenia
model
similarli
threshold
cellsmm
evalu
detect
kipyv
wupyv
predictor
clinic
outcom
includ
diagnosi
grade
acut
gvhd
cmv
reactiv
neutropenia
lymphopenia
hospit
within
day
viral
symptom
increas
liver
transaminas
total
bilirubin
level
death
within
year
timetoev
outcom
patient
record
censor
date
last
contact
death
kipyv
wupyv
detect
treat
timedepend
covari
cox
regress
model
potenti
confound
model
includ
age
sex
donor
type
stem
cell
sourc
condit
regimen
outcom
multipl
occurr
time
analyz
function
recent
kipyv
wupyv
detect
use
logist
linear
regress
model
viru
detect
within
last
week
defi
ned
posit
sampl
current
last
studi
contact
lag
time
day
viru
detect
within
last
month
analyz
wheez
cough
symptom
may
persist
defi
ned
posit
sampl
current
last
studi
contact
long
contact
occur
within
day
model
adjust
detect
respiratori
viru
within
last
week
day
rel
transplant
age
condit
regimen
donor
type
acut
gvhd
measur
base
multipl
patient
contact
enter
repeat
measur
adjust
possibl
correl
valu
within
person
use
gener
estim
equat
regress
model
p
valu
obtain
use
wald
test
adjust
made
multipl
comparison
twosid
p
valu
consid
signifi
cant
analys
perform
use
sa
version
sa
institut
cari
nc
usa
total
nasal
wash
specimen
collect
elig
patient
weekli
longer
interv
median
day
rang
day
cohort
median
specimen
per
patient
rang
specimen
patient
rang
age
month
year
median
year
remain
studi
median
day
rang
day
hct
respiratori
viru
detect
specimen
patient
sampl
posit
respiratori
viru
time
studi
clinic
characterist
cohort
provid
tabl
kipyv
wupyv
dna
detect
specimen
patient
specimen
patient
respect
two
patient
posit
virus
patient
posit
concurr
specimen
addit
patient
posit
viru
differ
specimen
among
wupyvposit
kipyvposit
patient
patient
provid
specimen
studi
year
hct
cumul
incid
estim
ci
kipyv
ci
wupyv
figur
kipyv
wupyv
fi
rst
detect
median
day
rang
day
day
rang
day
transplant
respect
kipyvposit
wupyvposit
specimen
detect
everi
month
appar
season
figur
respiratori
viru
detect
kipyvposit
wupyvposit
specimen
rhinovirus
coronavirus
account
respiratori
viru
codetect
respiratori
kipyv
virus
tend
cooccur
odd
ratio
ci
p
twentyon
kipyvposit
wupyvposit
patient
posit
specimen
posit
episod
detect
consecut
specimen
seen
kipyvposit
patient
includ
consist
posit
specimen
figur
panel
wupyvposit
patient
includ
consecut
specimen
figur
panel
b
maximum
number
log
copiesml
kipyv
wupyv
viru
per
posit
episod
rang
median
median
respect
patient
kipyvposit
specimen
averag
log
higher
maximum
viral
log
copiesml
median
kipyvposit
patient
posit
specimen
median
p
consid
posit
sampl
number
kipyv
copiesml
signifi
cantli
higher
specimen
posit
kipyv
respiratori
viru
specimen
kipyv
viru
detect
median
vs
respect
p
contrast
wupyvposit
specimen
respiratori
viru
copathogen
signifi
cantli
lower
viral
copi
number
specimen
posit
wupyv
viru
alon
median
vs
respect
p
patient
age
transplant
correl
kipyv
wupyv
copiesml
time
studi
number
specimen
collect
differ
among
patient
accord
polyomaviru
detect
age
year
signifi
cant
predictor
kipyv
wupyv
detect
multivari
model
hazard
ratio
hr
ci
p
hr
ci
p
respect
patient
year
age
patient
year
age
posit
kipyv
wupyv
compar
patient
year
age
figur
detect
respiratori
viru
within
last
week
signifi
cant
predictor
kipyv
detect
hr
ci
p
model
adjust
age
transplant
type
donor
type
cmv
reactiv
neutropenia
lymphopenia
associ
detect
kipyv
wupyv
within
fi
rst
day
transplant
detect
kipyv
within
past
week
significantli
associ
sputum
product
ci
p
tabl
wupyv
detect
within
past
month
signifi
cantli
associ
wheez
ci
p
limit
analysi
patient
high
level
kipyv
detect
within
past
week
log
copiesml
show
signifi
cant
associ
sputum
product
ci
p
analysi
symptom
function
kipyv
posit
among
patient
respiratori
viru
detect
within
past
week
show
similar
associ
sputum
product
kipyv
detect
ci
p
longitudin
analys
show
signifi
cant
relationship
wupyv
detect
lower
risk
lymphopenia
defi
ned
cellsmm
ci
p
grade
acut
gvhd
hr
ci
p
model
adjust
donor
type
stem
cell
sourc
among
patient
given
diagnos
grade
acut
gvhd
respect
howev
associ
base
case
patient
wupyv
detect
gvhd
diagnosi
relationship
detect
kipyv
wupyv
cmv
reactiv
risk
hospit
day
transplant
mean
valu
alanin
aminotransferas
aspart
aminotransferas
total
bilirubin
level
found
multivari
model
nineteen
bronchoalveolar
lavag
bal
sampl
kipyvposit
patient
bal
sampl
kipyvneg
wupyvneg
patient
test
kipyv
wupyv
collect
bal
sampl
occur
within
week
posit
nasal
wash
sampl
kipyvposit
patient
includ
collect
day
bal
sampl
posit
kipyv
log
copiesml
sampl
collect
child
day
kipyvposit
nasal
wash
sampl
day
transplant
cmv
also
isol
cultur
patient
receiv
treatment
cmv
pneumonia
death
within
year
transplant
occur
patient
posit
kipyv
patient
posit
wupyv
patient
posit
kipyv
wupyv
neither
viru
associ
mortal
rate
adjust
model
larg
longitudin
surveil
studi
provid
rigor
evalu
kipyv
wupyv
detect
upper
respiratori
tract
specimen
hct
recipi
oneyear
cumul
incid
estim
high
kipyv
wupyv
respect
prolong
episod
detect
week
patient
posit
kipyv
patient
posit
wupyv
number
compar
report
rhinovirus
coronavirus
common
respiratori
viru
type
detect
patient
popul
found
day
estim
respect
detect
month
respect
comparison
crosssect
studi
test
specimen
immunocompet
children
acut
respiratori
tract
ill
found
preval
kipyv
wupyv
rang
recent
studi
pediatr
hematologyoncolog
patient
immunocompet
person
found
higher
kipyv
mean
viral
load
respiratori
tract
specimen
immunocompromis
group
suggest
potenti
increas
pathogen
popul
studi
adult
hct
recipi
test
sequenti
nasopharyng
aspir
asymptomat
patient
kipyv
wupyv
detect
sampl
crosssect
studi
test
specimen
hct
recipi
respiratori
ill
detect
kipyv
similar
fi
nding
wupyv
detect
respiratori
virus
often
codetect
cohort
kipyv
wupyv
consist
high
rate
coinfect
report
other
studi
young
age
risk
factor
detect
kipyv
wupyv
report
seropreval
antibodi
kipyv
wupyv
children
year
age
similar
adult
suggest
primari
exposur
occur
childhood
also
found
detect
respiratori
viru
within
previou
week
independ
risk
factor
detect
kipyv
compar
sampl
kipyv
dna
detect
higher
viral
copi
number
kipyv
detect
sampl
also
posit
respiratori
viru
perhap
stimul
viral
replic
respiratori
viru
infect
current
data
provid
evid
biolog
meaning
differ
prolong
detect
younger
age
associ
higher
preval
kipyv
wupyv
also
report
longitudin
studi
kipyv
wupyv
children
bk
jc
polyomavirus
kipyv
wupyv
might
persist
life
primari
infect
undetermin
site
becom
reactiv
period
immun
suppress
prolong
detect
episod
may
repres
longterm
viral
shed
new
acquisit
viru
especi
young
patient
reactiv
stimul
replic
persist
viru
respiratori
tract
immun
suppress
recent
concomit
respiratori
viru
infect
site
persist
new
polyomavirus
yet
identifi
ed
although
human
tonsil
postul
reservoir
reactiv
demonstr
lymph
node
spleen
longitudin
design
studi
specimen
collect
symptomat
asymptomat
period
enabl
us
thoroughli
evalu
symptom
associ
kipyv
wupyv
detect
hct
recipi
found
kipyv
detect
past
week
associ
sputum
product
wupyv
detect
past
month
associ
wheez
limit
analysi
patient
high
viral
copi
number
kipyv
nasal
wash
sampl
provid
addit
associ
likewis
codetect
kipyv
respiratori
viru
associ
symptom
sputum
product
suggest
infect
kipyv
exacerb
symptom
caus
respiratori
viru
patient
underw
bronchoscopi
workup
possibl
lower
respiratori
ill
bal
specimen
avail
test
detect
kipyv
sampl
child
also
cmv
pneumonia
overal
analys
provid
support
virus
respiratori
pathogen
howev
observ
sever
respiratori
ill
death
could
conclus
attribut
polyomaviru
detect
seek
biolog
plausibl
clinic
relev
associ
new
virus
found
associ
kipyv
wupyv
detect
nasal
wash
es
cmv
reactiv
increas
liver
enzym
level
hospit
neutropenia
fi
rst
day
transplant
detect
wupyv
associ
lower
risk
lymphopenia
test
sampl
blood
urin
fece
kipyv
wupyv
dna
previou
studi
report
detect
virus
plasma
serum
peripher
blood
sampl
patient
infect
healthi
blood
donor
children
urin
sampl
children
immunocompet
immunocompromis
adult
wupyv
detect
serum
fece
children
whose
nasopharyng
aspir
sampl
contain
high
viral
load
virus
detect
fecal
sampl
hct
recipi
associ
found
kipyv
diarrhea
howev
fi
nd
associ
viru
diarrhea
anoth
limit
although
report
prolong
uninterrupt
kipyv
wupyv
detect
perform
genet
analys
confi
rm
whether
detect
repres
differ
viral
subtyp
conclus
detect
kipyv
wupyv
one
third
allogen
hct
recipi
fi
rst
year
transplant
prolong
detect
episod
high
viral
copi
number
respiratori
specimen
also
observ
howev
observ
mani
associ
acut
respiratori
symptom
found
detect
respiratori
viru
risk
factor
kipyv
detect
concurr
detect
polyomavirus
respiratori
virus
common
although
suggest
kipyv
wupyv
might
major
pathogen
immunosuppress
patient
fi
nd
clear
role
virus
respiratori
pathogen
classic
upper
lower
respiratori
tract
symptom
time
recommend
routin
test
virus
immunocompromis
patient
inclus
multiplex
respiratori
viru
pcr
panel
investig
examin
specimen
type
bal
blood
urin
larger
patient
cohort
longer
period
time
may
necessari
elucid
role
virus
highli
immunocompromis
patient
